HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Second radiation plus drug shows promise for Tough-to-Treat head and neck cancer
Disease control Recruiting nowThis early-phase study tests whether giving a second round of radiation together with a drug called chidamide is safe for people whose head and neck cancer has come back after previous radiation. Only 6 participants will be enrolled to find the best dose and check for side effect…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 01, 2026 17:28 UTC
-
New drug STRO-004 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called VMD-928, taken as a pill, alone or with pembrolizumab (an immunotherapy) in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug shrinks t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
Can Six-Day radiation beat Five-Day for head & neck cancer?
Disease control Recruiting nowThis study looks at whether giving radiation therapy six days a week (instead of the usual five) can better control head and neck cancer in people who start treatment more than six weeks after surgery. About 75 adults with intermediate- or high-risk head and neck cancer will take…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New drug EPI-326 takes on tough cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in people with advanced lung cancer (with a specific EGFR mutation) or head/neck cancer. The main goals are to check safety and find the best dose. About 110 participants will receive the drug to see if it can shrink tumors a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New study aims to cut radiation for head and neck cancer patients
Disease control Recruiting nowThis study looks at whether people with advanced head and neck cancer who had a good response to chemo-immunotherapy before surgery can safely receive less radiation afterward. About 50 participants will be followed for two years to see if the cancer stays away and if their quali…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New drug EXS74539 enters first human tests for tough cancers
Disease control Recruiting nowThis early-stage study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug sh…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 1,300 participants …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New drug duo shows promise against aggressive head and neck cancer
Disease control Recruiting nowThis study tests whether giving two drugs—ficerafusp alfa and pembrolizumab—before surgery can shrink tumors in people with advanced head and neck cancer. About 32 participants with resectable, PD-L1-positive tumors will receive the combination, then have surgery. The main goal i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
App aims to catch cancer treatment side effects early, prevent dangerous weight loss
Symptom relief Recruiting nowThis study tests whether using a smartphone app to regularly report symptoms during radiation therapy can help head and neck cancer patients avoid severe weight loss. About 192 adults receiving curative treatment will be monitored remotely. The goal is to catch problems early and…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Symptom relief
Last updated Apr 29, 2026 15:04 UTC
-
Scientists gather key materials to create personalized cell therapies for Hard-to-Treat cancers
Knowledge-focused Recruiting nowThis study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. Researchers will analyze the tumors for genetic changes and store participants' own T cells for possible future use in making a personalized CA…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:48 UTC